Dr. Sharma on Tolerability of SIRT in Patients With CRC

Navesh K. Sharma, DO, PhD
Published: Thursday, Sep 01, 2016


Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the safety profile of selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 when added to chemotherapy with or without bevacizumab (Avastin) for patients with colorectal cancer (CRC) that has metastasized to the liver.

Findings thus far demonstrate that the addition improves liver disease, leading to a significant improvement in progression-free survival.

SIRT was found to be very well tolerated among patients, Sharma explains. In examining the toxicities, there were no unexpected or additional events, except for a few mild toxicities in the SIRT arm, he adds.
SELECTED
LANGUAGE

Dr. Navesh K. Sharma, associate professor of Radiology in the Division of Radiology and Oncology at Penn State Hershey Medical Center and section chief of Radiation Oncology at the Penn State Health St. Joseph Cancer Center, discusses the safety profile of selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 when added to chemotherapy with or without bevacizumab (Avastin) for patients with colorectal cancer (CRC) that has metastasized to the liver.

Findings thus far demonstrate that the addition improves liver disease, leading to a significant improvement in progression-free survival.

SIRT was found to be very well tolerated among patients, Sharma explains. In examining the toxicities, there were no unexpected or additional events, except for a few mild toxicities in the SIRT arm, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x